Cryoport, Inc. · NASDAQ:CYRX
Cryoport — Jefferies Global Healthcare Conference 2026
22 slides from Cryoport's conference presentation, June 2026
Slide 1: Enabling the Future of Medicine
Enabling the Future of MedicineTM Jerrell Shelton, CEO June 2026 Jefferies Global Healthcare Conference
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation which are not purely historical, including statements regarding Cryoport’s intentions, hopes, beliefs, expectations, representations, projects, plans or predictions of the future, are forward-looking statements within the meaning of the Priv
Slide 3: Global leader in temperature-controlled supply chain solutions for the Life Sciences
Global leader in temperature-controlled supply chain solutions for the Life Sciences with emphasis on the rapidly growing Cell & Gene Therapy market © 2026 CRYOPORT, INC. 3
Slide 4: Ecosystem for Cell Therapy
Ecosystem for Cell Therapy Where we fit Biology Engineering & Temperature-controlled Manufacturing Supply Chain Digital © 2026 CRYOPORT, INC. CONFIDENTIAL |4
Slide 5: Cryoport Snapshot – By the Numbers
Cryoport Snapshot – By the Numbers Leading integrated platform ensuring the integrity of critical biomaterials across the life sciences value chain $47.8M $192-$196M 46% ($0.6M) +16% Organic Growth +9-11% Organic Growth +42bps YoY $2.2M Improvement YoY Q1 FY2026 FY2026 Q1 FY2026 Q1 FY2026 Adjusted R
Slide 6: Q1 2026 Revenue Drivers
Q1 2026 Revenue Drivers Strong double-digit growth across the platform of products and services +21% +26% Commercial Cell BioServices & & Gene Therapy Revenue +18% Biostorage Revenue +15% Life Sciences Services Revenue Life Sciences Products Revenue Q1 FY2026 Revenue Strong Growth +16% Across All Se
Slide 7: Cryoport Snapshot – Revenue Mix
Cryoport Snapshot – Revenue Mix Leading integrated platform ensuring the integrity of critical biomaterials across the life sciences value chain Q1 FY2026 Revenue Type Geography Cell & Gene Therapy Revenue 8% 19% 41% 44% 56% 59% 73% Services Americas Clinical Products EMEA Commercial APAC © 2026 CRY
Slide 8: Serving The High Growth $10B+ CGT Market
Serving The High Growth $10B+ CGT Market Expanding pipeline, rising trial activity, and growing patient populations underpin durable growth opportunities for Cryoport CGT Clinical Activity(1) CGT Commercial Market(2) CAGR: ~30% $38B CAGR: ~17% $25B $10B 2025E 2030E Existing Commercial Therapies New
Slide 9: Cryoport - the Leading Service Provider for CGT
Cryoport - the Leading Service Provider for CGT Deeply embedded with customers and partners with significant barriers to entry Global CGT Clinical Trials(1) Global Commercial Therapies(2) Number & share of global, active cell & gene therapy clinical trials (excl. pre-clinical) Revenue from commercia
Slide 10: The Cryoport Platform: Services & Products
The Cryoport Platform: Services & Products Core services and products supporting the management of critical biomaterials Life Sciences Services 56% Life Sciences Products 44% +18% YoY +15% YoY Q1 FY2026 Q1 FY2026 BioLogistics IntegriCell® BioServices BioStorage Cryogenic Systems (Launched in 2024) (
Slide 11: The Cryoport Platform: End-to-End Support
The Cryoport Platform: End-to-End Support Comprehensive supply chain management of cell & gene therapies throughout the full workflow – upstream and downstream Manufacturing Transfer to Secure Storage Manufacturer of Therapy Material Management Packaging, Fulfillment & Secure Storage & Kit Productio
Slide 12: The Cryoport Platform: BioLogistics
The Cryoport Platform: BioLogistics Leading provider of global temperature-controlled, compliant biomaterials handling, focused on cell & gene therapies BioLogistics Overview • Patented, ISO 21973-compliant systems and processes designed specifically for life sciences, enabling secure, temperature-
Slide 13: Regulatory Discipline and Compliance
Regulatory Discipline and Compliance Assurance of global regulatory compliance End-to-end control Chain-of-custody, chain-of- FDA-registered and audit- GxP-compliant quality mitigating risk from identity, chain-of-condition, ready operations across systems aligned with ISO vendor hand-offs and full
Slide 14: The Cryoport Platform: IntegriCell
The Cryoport Platform: IntegriCell® Manufacturing-ready leukopak and cryopreservation services and processes for cell therapy IntegriCell® Overview • Standardized solution for the collection, processing, and preservation of cell & gene therapy starting materials • Ready-to-use leukapheresis protocol
Slide 15: The Cryoport Platform: BioServices
The Cryoport Platform: BioServices Centralized biomaterials storage, fulfillment, and related services for allogeneic and autologous cell & gene therapies BioServices Overview • Network of state-of-the-art facilities for GMP biostorage, clinical and commercial sample management, and inventory contro
Slide 16: The Cryoport Platform: BioStorage
The Cryoport Platform: BioStorage Secure and compliant biorepository for longer-term, temperature-controlled storage BioStorage Overview • Specialized biorepository services providing secure, long-term multi-temperature cryogenic storage for biological specimens and pre-clinical materials • Regulato
Slide 17: The Cryoport Platform: Cryogenic Systems
The Cryoport Platform: Cryogenic Systems Leading manufacturer globally MVE Biological Solutions Overview MVE Product Family • Advanced cryogenic transport, storage, and containment systems with next-generation cryogenic systems technologies Bulk storage • Diverse base of direct customers including b
Slide 18: Advanced Integrated Digital Platform
Advanced Integrated Digital Platform Advanced Integrated Digital Platform Proprietary digital infrastructure unifying services, equipment, data, and users into a single source for end-to-end visibility Cryoportal® Digital Management Platform Tech Stack Distributors & Pharma & Hospitals, Cryoport Emb
Slide 19: Comprehensive Global Supply Chain Capabilities
Comprehensive Global Supply Chain Capabilities BioLogistics IntegriCell® BioServices BioStorage Cryogenic Systems Mfg Americas EMEA APAC HQ Expanding Capabilities Globally Paris, FRANCE (H2’25) Santa Ana, USA (Expected H2’26) Tampa, USA (Expected mid-’27) Global Supply Chain Center Global Supply Cha
Slide 20: Patients First: Supporting the Therapies of Tomorrow
Patients First: Supporting the Therapies of Tomorrow Clinical Trials Supported, by Trial Phase 21 Commercial Therapies Supported Phase I Phase II Phase III 766 アクーゴ 760 701 AKUUGO® 675 654 86 91 602 81 79 82 74 361 357 311 321 300 273 255 275 282 299 313 318 ® 2021 2022 2023 2024 2025 Q1 2026 CGT In
Slide 21: Cryoport's Leadership in the Life Sciences
Cryoport’s Leadership in the Life Sciences Global market leader in temperature-controlled supply chain services Scalable platform with expanding suite of integrated services Deeply embedded in majority of cell & gene clinical and commercial therapies World’s leading cryogenic systems manufac
Slide 22: Thank you!
Join us in “Enabling the Future of Medicine ” Thank you! https://www.cryoport.com/ https://ir.cryoportinc.com/
Cryoport — Jefferies Global Healthcare Conference 2026 on 6ix